Clinical Trial Update: A Phase III Randomized, Double-blind, Placebo Controlled Trial Comparing the Efficacy of Gemcitabine, Cisplatin and Sorafenib to Gemcitabine, Cisplatin and Placebo in First-Line Treatment of Patients With Stage IIIb With Effusion and Stage IV Non-Small Cell Lung Cancer (NSCLC) [Phase 3]

View source ↗

Summary

A Phase III randomized trial compared Gemcitabine, Cisplatin, and Sorafenib versus Gemcitabine, Cisplatin, and Placebo as first-line therapy for stage IIIb with…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• CISPLATIN (cisplatin)
• Gemzar (gemcitabine)
• Sorafenib (Sorafenib)

Snippet

Sponsor: Bayer | Conditions: Carcinoma, Non-Small-Cell Lung | Phase 3 | Status: COMPLETED | Results posted: 2011-09-09